Toba, Michie Alzoubi, Abdallah O’Neill, Kealan Abe, Kohtaro Urakami, Takeo Komatsu, Masanobu Alvarez, Diego Järvinen, Tero A.H. Mann, David Ruoslahti, Erkki
...
Published in
The American Journal of Pathology
A major limitation in the pharmacological treatment of pulmonary arterial hypertension (PAH) is the lack of pulmonary vascular selectivity. Recent studies have identified a tissue-penetrating homing peptide, CARSKNKDC (CAR), which specifically homes to hypertensive pulmonary arteries but not to normal pulmonary vessels or other tissues. Some tissue...
Urakami, Takeo Järvinen, Tero A.H. Toba, Michie Sawada, Junko Ambalavanan, Namasivayam Mann, David McMurtry, Ivan Oka, Masahiko Ruoslahti, Erkki Komatsu, Masanobu
...
Published in
The American Journal of Pathology
Pulmonary arterial hypertension (PAH) is a disorder of the pulmonary vasculature associated with elevated pulmonary vascular resistance. Despite recent advances in the treatment of PAH, with eight approved clinical therapies and additional therapies undergoing clinical trials, PAH remains a serious life-threatening condition. The lack of pulmonary ...
